Breaking down the walls of immunological ignorance

February 27, 2002

T cells that respond to an antigen challenge in vitro but fail to do so in a living animal are said to be in a state of immunological ignorance. Chen and his colleagues have argued for some time that this poorly understood state can help explain the workings and, crucially, the failings of immunological surveillance for tumors. Ignorance of tumor antigens has been ascribed to the lack of costimulatory signals, and it appears that one strategy of immune evasion by tumors is the down regulation of otherwise common costimulatory activators. Still, some experimentally induced tumors, expressing known tumor antigens that are targeted by defined CTL clones, can be eliminated when T cells are provided an additional, costimulatory signal. In their current report, Wilcox et al. develop a useful reagent for this purpose, and they show that such a co-stimulatory treatment is not always sufficient to induce tumor regression. The authors injected a monoclonal antibody to the costimulatory mediator CD137, a T cell?borne relative of the TNF receptor. This novel agonistic antibody stimulates the expansion and activation of the necessary CTL clone, allowing animals with one type of carcinoma undergo a dramatic tumor regression following treatment. Interestingly, another tumor type, a thymoma that displays the same tumor antigen, is refractory to this treatment, indicating that the CTLs remain ignorant of the antigen when it occurs in the latter context. Wilcox et al. find that this ignorant state can be overcome when the animals are provided not just the agonistic antibody, but also an antigenic peptide recognized by the tumor-specific CTL. Hence, they argue that either inadequate levels of the presented antigen or insufficient costimulatory signaling through CD137 can lead to immunological ignorance and allow tumor growth to proceed unchecked. Providing one or both of these signals might therefore heighten the efficiency of tumor surveillance in animals with spontaneous tumors as well.
-end-


JCI Journals

Related Tumors Articles from Brightsurf:

A viable vaccine for tough tumors
While immunotherapies work well for some cancers, others are immune-resistant and condemn patients to the severe side effects of long-term chemo treatment.

Women could conceive after ovarian tumors
Women receiving fertility-sparing surgery for treatment of borderline ovarian tumours were able to have children, a study from Karolinska Institutet in Sweden published in Fertility & Sterility shows.

Attacking tumors from the inside
A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer (NSCLC), helping to suppress the tumor's growth and spread, UT Southwestern researchers report.

Directing nanoparticles straight to tumors
Modern anticancer therapies aim to attack tumor cells while sparing healthy tissue.

A solid vaccine for liquid tumors
Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years.

Evolutionarily novel genes work in tumors
A team of scientists from Peter the Great St. Petersburg Polytechnic University studied the evolutionary ages of human genes and identified a new class of them expressed in tumors -- tumor specifically expressed, evolutionarily novel (TSEEN) genes.

Identification of all types of germ cells tumors
Germ cell tumors were considered very heterogeneous and diverse, until recently.

Laser light detects tumors
A team of researchers from Jena presents a groundbreaking new method for the rapid, gentle and reliable detection of tumors with laser light.

Better prognosticating for dogs with mammary tumors
For dogs with mammary tumors, deciding a course of treatment can depend on a variety of factors, some of which may seem to contradict one another.

The evolution of brain tumors
Scientists from the German Cancer Research Center found in a recent study that only three different genetic alterations drive the early development of malignant glioblastomas.

Read More: Tumors News and Tumors Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.